Accueil > Actualité
Actualite financiere : Actualite bourse

AstraZeneca: agreement with Ionis on Eplontersen

( - AstraZeneca announces that it has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals for eplontersen, an investigational drug designed to reduce the production of transthyretin (TTR protein) in amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN).

The companies will jointly develop and market eplontersen in the United States, while AstraZeneca will develop and market it in the rest of the world, excluding Latin America.

ATTR-CM is a systemic, progressive and fatal disease that leads to progressive heart failure and death within four years of diagnosis, while ATTR-PN is usually fatal within ten years, the laboratory says.

Copyright (c) 2021 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.